ilorasertib   Click here for help

GtoPdb Ligand ID: 9914

Synonyms: A-968660 | ABT 348 | ABT-348 | ABT348
Compound class: Synthetic organic
Comment: Ilorasertib (ABT-348) is an ATP-competitive, multi-target kinase inhibitor with activity against the Aurora kinases, the VEGFR, PDGFR and Src family kinases [1].
ABT-348's potent inhibition of Aurora B induces polyploidy, a hallmark of the essential role of Aurora B in cytokinesis.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 4
Rotatable bonds 8
Topological polar surface area 146.33
Molecular weight 488.14
XLogP 3.66
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES OCCn1ncc(c1)c1cnc(c2c1scc2c1ccc(cc1)NC(=O)Nc1cccc(c1)F)N
Isomeric SMILES OCCn1ncc(c1)c1cnc(c2c1scc2c1ccc(cc1)NC(=O)Nc1cccc(c1)F)N
InChI InChI=1S/C25H21FN6O2S/c26-17-2-1-3-19(10-17)31-25(34)30-18-6-4-15(5-7-18)21-14-35-23-20(12-28-24(27)22(21)23)16-11-29-32(13-16)8-9-33/h1-7,10-14,33H,8-9H2,(H2,27,28)(H2,30,31,34)
No information available.
Summary of Clinical Use Click here for help
Phase 1 studies of ABT-348 have been completed in patients with ALL, AML, B cell CLL, and advanced solid malignaicies. A Phase 2 trial in CDKN2A deficient solid tumours (NCT02478320) is underway.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02478320 Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors Phase 2 Interventional M.D. Anderson Cancer Center